TUBITAK Destekli Projelerden Çıkan Yayınlar Topluluğu
Yayınlanmış 1 Ocak 2022 | Sürüm v1
Dergi makalesi Açık

The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

Oluşturanlar

  • 1. Univ Catania, Dept Clin & Expt Med, Psychiat Unit, Catania, Italy
  • 2. Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Med Ctr, Maastricht, Netherlands
  • 3. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
  • 4. Gazi Univ, Fac Med, Dept Psychiat, Ankara, Turkey
  • 5. Univ Hlth Sci, Dept Psychiat, Ankara Diskapi Training & Res Hosp, Ankara, Turkey
  • 6. Univ Utrecht, Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Dept Translat Neurosci, Utrecht, Netherlands
  • 7. Dokuz Eylul Univ, Fac Med, Dept Psychiat, Izmir, Turkey
  • 8. Adnan Menderes Univ, Fac Med, Dept Psychiat, Aydin, Turkey
  • 9. Dokuz Eylul Univ, Grad Sch Hlth Sci, Dept Neurosci, Izmir, Turkey
  • 10. Middle East Tech Univ, Dept Psychol, Ankara, Turkey
  • 11. Turkish Federat Schizophrenia Assoc, Ankara, Turkey
  • 12. Guven Cayyolu Healthcare Campus, Ankara, Turkey
  • 13. Ataturk Res & Training Hosp Psychiat Clin, Ankara, Turkey

Açıklama

Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples. (C) 2022 The Author(s). Published by Elsevier B.V.

Dosyalar

bib-4483a829-e05a-4d93-9317-31754239322d.txt

Dosyalar (466 Bytes)

Ad Boyut Hepisini indir
md5:1ee1dc5ba49fa2c1325b0812b462b2e8
466 Bytes Ön İzleme İndir